Calithera Biosciences Inc. (CALA) Stock Price Down 2.1%
Calithera Biosciences Inc. (NASDAQ:CALA) shares dropped 2.1% during mid-day trading on Tuesday . The company traded as low as $3.14 and last traded at $3.28, with a volume of 120,352 shares trading hands. The stock had previously closed at $3.35.
CALA has been the topic of a number of recent analyst reports. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Calithera Biosciences has a consensus rating of “Buy” and a consensus price target of $10.38.
The stock’s market capitalization is $63.53 million. The company’s 50 day moving average price is $3.29 and its 200 day moving average price is $4.76.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.03. On average, equities research analysts anticipate that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current fiscal year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.